TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
IDEAYA Biosciences ( (IDYA) ) has shared an update.
On December 4, 2025, GlaxoSmithKline announced its decision to terminate its collaboration with IDEAYA Biosciences, effective ninety days from the notice. During this transition period, GSK will transfer the Werner Helicase and Pol Theta clinical programs back to IDEAYA, which plans to evaluate strategic options for these programs in 2026, maintaining its cash runway expectations into 2030.
The most recent analyst rating on (IDYA) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.
Spark’s Take on IDYA Stock
According to Spark, TipRanks’ AI Analyst, IDYA is a Neutral.
IDEAYA Biosciences’ stock score is primarily influenced by its strong technical momentum, which is offset by significant financial performance challenges and valuation concerns. The company’s robust equity position provides some stability, but strategic improvements are necessary to address profitability and cash flow issues.
To see Spark’s full report on IDYA stock, click here.
More about IDEAYA Biosciences
IDEAYA Biosciences operates in the biotechnology industry, focusing on developing precision medicine and immuno-oncology therapies. The company is engaged in clinical programs targeting specific genetic mutations and pathways.
Average Trading Volume: 1,193,297
Technical Sentiment Signal: Buy
Current Market Cap: $3.16B
Learn more about IDYA stock on TipRanks’ Stock Analysis page.